Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Vinorelbine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 104 Carcinoma, Non-Small-Cell Lung 54 Lung Neoplasms 24 Hodgkin Disease 14 Lymphoma 10 Triple Negative Breast Neoplasms 8 Prostatic Neoplasms 7 Neoplasms 7 Recurrence 6 Neoplasm Metastasis 6 Small Cell Lung Carcinoma 5 Lymphoma, Large B-Cell, Diffuse 5 Sarcoma 4 Rhabdomyosarcoma 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Breast Neoplasms, Male 4 Ovarian Neoplasms 3 NSCLC 3 Multiple Myeloma 3 Mesothelioma, Malignant 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 3 Lymphoma, Large-Cell, Immunoblastic 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia 3 Esophageal Squamous Cell Carcinoma 3 Burkitt Lymphoma 3 Brain Neoplasms 3

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡